ARTICLE | Company News
Bradley, Quintiles, SkyePharma deal
August 16, 2004 7:00 AM UTC
BDY completed its previously announced acquisition of QTRN's dermatology subsidiary, Bioglan Pharmaceuticals Co. (Malvern, Penn.), for $183 million in cash (see BioCentury, June 14). The closing trigg...